University of Cagliari

About: University of Cagliari is a education organization based out in Cagliari, Italy. It is known for research contribution in the topics: Population & Dopamine. The organization has 11029 authors who have published 29046 publications receiving 771023 citations. The organization is also known as: Università degli Studi di Cagliari & Universita degli Studi di Cagliari.

Predictors of morbidity and mortality in acromegaly: an Italian survey

Abstract: Objective: To describe demographic and hormonal characteristics, comorbidities (diabetes mellitus and hypertension), therapeutic procedures and their effectiveness, as well as predictors of morbidity and mortality in a nationwide survey of Italian acromegalic patients Design: Retrospective multicenter epidemiological study endorsed by the Italian Society of Endocrinology and performed in 24 tertiary referral Italian centers The mean follow-up time was 120 months Results: A total of 1512 patients, 41% male, mean age: 45G13 years, mean GH: 31G37 mg/l, IGF1: 744 G318 ng/ml, were included Diabetes mellitus was reported in 16% of cases and hypertension in 33% Older age and higher IGF1 levels at diagnosis were significant predictors of diabetes and hypertension At the last follow-up, 65% of patients had a controlled disease, of whom 55% were off medical therapy Observed deaths were 61, with a standardized mortality ratio of 113 95% (confidence interval (CI): 087‐146) Mortality was significantly higher in the patients with persistently active disease (193; 95% CI: 134‐270) Main causes of death were vascular diseases and malignancies with similar prevalence A multivariate analysis showed that older age, higher GH at the last follow-up, higher IGF1 levels at diagnosis, malignancy, and radiotherapy were independent predictors of mortality Conclusions: Pretreatment IGF1 levels are important predictors of morbidity and mortality in acromegaly The full hormonal control of the disease, nowadays reached in the majority of patients with modern management, reduces greatly the disease-related mortality

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.

Abstract: BACKGROUND AND OBJECTIVES: Deferasirox (ICL670) is a novel once-daily oral iron chelator developed for the treatment of chronic iron overload from blood transfusions. This study evaluated the safety and tolerability of deferasirox in pediatric patients with transfusion-dependent beta-thalassemia major. Efficacy and pharmacokinetic assessments were secondary objectives. DESIGN AND METHODS: Forty patients equally stratified into two age groups--children (2 to

Overview of the JET results in support to ITER

Abstract: The 2014-2016 JET results are reviewed in the light of their significance for optimising the ITER research plan for the active and non-active operation. More than 60 h of plasma operation with ITER first wall materials successfully took place since its installation in 2011. New multi-machine scaling of the type I-ELM divertor energy flux density to ITER is supported by first principle modelling. ITER relevant disruption experiments and first principle modelling are reported with a set of three disruption mitigation valves mimicking the ITER setup. Insights of the L-H power threshold in Deuterium and Hydrogen are given, stressing the importance of the magnetic configurations and the recent measurements of fine-scale structures in the edge radial electric. Dimensionless scans of the core and pedestal confinement provide new information to elucidate the importance of the first wall material on the fusion performance. H-mode plasmas at ITER triangularity (H = 1 at β N ∼ 1.8 and n/n GW ∼ 0.6) have been sustained at 2 MA during 5 s. The ITER neutronics codes have been validated on high performance experiments. Prospects for the coming D-T campaign and 14 MeV neutron calibration strategy are reviewed.